Shares of drugmaker Moderna (MRNA.O) surge 105% to an over two-year high of $129.43, while Merck (MRK.N) was up 10% in morning trading, hitting a record high
MRNA stock is set for the biggest one-day percentage jump if gains hold
Including session's move, MRNA more than quadrupled and MRK was up 41% YTD
Trial results for personalized skin cancer vaccine
MRNA's personalized skin cancer vaccine in combination with MRK's blockbuster immunotherapy Keytruda reduced skin cancer recurrence and spread compared with Keytruda alone in a late-stage trial, the companies say
The treatment combines Merck's Keytruda with a made-to-order mRNA vaccine from Moderna that is based on an analysis of mutations found in the patients' own tumors
The trial enrolled 1,137 high-risk patients with stage IIB-IV melanoma that had been surgically removed
Melanoma is the deadliest form of skin cancer. In 2023, more than 1.5 million people were living with melanoma in the U.S., according to National Cancer Institute data
MRNA•
